Abstract
Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disease in the Republic of Ireland (ROI), with a previously quoted incidence of 1 in 1353 and carrier rate of 1 in 19. The National Newborn Screening (NBS) for CF was incorporated in July 2011 in the ROI. A cut-off point of the top 1% Immunoreactive Trypsinogen (IRT) was taken as an indication for 38 CFTR variant panel to maximise identification of affected CF cases and to minimise detection of carriers. All neonates from July 2011 to Dec 2017 with an elevated IRT on NBS were tested with 38 CFTR mutation panel and included. Clinical and laboratory database were analysed. In the first 6.5 years a total of 5,053 newborns (1.16% of total births) were screened with 38 CFTR panel. 170 CF affected cases, 320 unaffected carriers, 32 CF Screening Positive Inconclusive Diagnosis (CFSPID) were identified. There was one missed diagnosis. The most common disease-causing variant was c.1521_1523delCTT (p.(Phe508del)) followed by c.1652G>A (p.(Gly551Asp)). 95 out of 170 (55%) affected newborns were homozygous for c.1521_1523delCTT (p.(Phe08del)) and 25 (15%) carried at least one copy of c.1652G>A (p.(Gly551Asp)). Hence, 70% of affected newborns were eligible for CFTR modulator treatment. The NBS programme has identified almost triple the number of affected newborn with c.1652G>A (p.(Gly551Asp)) than previously quoted figures and identified less than 50% of carriers than predicted. The revised incidence and carrier frequency of CF in the ROI is 1 in 2570 and 1 in 25, respectively.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Change history
05 July 2020
An amendment to this article has been published and can be accessed via a link at the top of the article.
References
Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J. 2007;100:557–60.
Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17:153–78. https://doi.org/10.1016/j.jcf.2018.02.006.
Dankert-Roelse JE, Vernooij-van Langen A. Newborn screening for cystic fibrosis: pros and cons. Breathe. 2011;8:24–30. https://doi.org/10.1183/20734735.004111.
Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respiratory Med. 2016;4:653–61. https://doi.org/10.1016/S2213-2600(16)00053-9.
A Practical Guide to Newborn Bloodspot Screening In Ireland. https://www.hse.ie/eng/health/child/newbornscreening/newbornbloodspotscreening/information-for-professionals/a-practical-guide-to-newborn-bloodspot-screening-in-ireland.pdf.
Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. J Pediatr. 2017;181S:S45–51.e1. https://doi.org/10.1016/j.jpeds.2016.09.066.
Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros. 2015;14:706–13. https://doi.org/10.1016/j.jcf.2015.01.001.
Health Research Board, Ireland. www.hrb.ie.
Central Statistic Office, Vital Statistic Annual Report. 2016 https://www.cso.ie/en/releasesandpublications/ep/p-vsar/vitalstatisticsannualreport2016/births2016/.
Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, et al. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. J Cyst Fibro. 2017;16:207–13. https://doi.org/10.1016/j.jcf.2016.12.012.
Massie J, Curnow L, Tzanakos N, Francis I, Robertson CF. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Arch Dis Child. 2006;91:222–5. https://doi.org/10.1136/adc.2005.081349.
Ong T, Ramsey BW. New therapeutic approaches to modulate and correct cystic fibrosis transmembrane conductance regulator. Pediatr Clin N Am. 2016;63:751–64. https://doi.org/10.1016/j.pcl.2016.04.006.
Ramsey BW, Davies J, McElvaney N, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–72. https://doi.org/10.1056/NEJMoa1105185.
ECFS patient registry annual data report. 2017. https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf.
US Cystic Fibrosis Foundation National Registry annual report. 2017 https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf.
Acknowledgements
We would like to express our deep gratitude to Prof. Philip Mayne, the former Head of the National Newborn Bloodspot Screening Laboratory, Department of Paediatric Laboratory Medicine at Children’s Health Ireland at Temple Street Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sasaki, E., Kostocenko, M., Lang, N. et al. National Newborn Screening for cystic fibrosis in the Republic of Ireland: genetic data from the first 6.5 years. Eur J Hum Genet 28, 1669–1674 (2020). https://doi.org/10.1038/s41431-020-0661-5
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41431-020-0661-5
This article is cited by
-
Image quality in ultra-low-dose chest CT versus chest x-rays guiding paediatric cystic fibrosis care
European Radiology (2025)
-
Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers
European Journal of Pediatrics (2022)
-
Setting a new standard in cystic fibrosis newborn screening illustrates controversial issues as new data emerge
European Journal of Human Genetics (2020)
